GUANGZHOU, China, Oct. 12 /Xinhua-PRNewswire-FirstCall/ -- China Medicine Corporation ("CMC") (OTC Bulletin Board: CHME), a leading distributor of prescription and over the counter pharmaceutical products, traditional Chinese medicines (finished medicines made of Chinese herbs), Chinese herbs, nutritional supplements, dietary supplements, medical supplies and medical formulations today announced the Company's ADTZ (Aflatoxin-detoxifizyme) project has been selected by Guangdong Province as one of six patent commercialization projects.
These selected six projects will receive financial and other support from the provincial and local government in order to assist in the rapid commercialization of the technologies.
Mr. Shenshan Yang, CEO of China Medicine stated, "Our ADTZ project has made tremendous progress and we believe that the financial and political support of the government will expedite commercialization of the product. We look forward to working closely with the government and a successful product launch."
About China Medicine Corporation
China Medicine is a distributor of medical products, traditional pharmaceutical medicines, traditional Chinese medicines, Chinese herbs and dietary supplements to over 28 provinces and 2,500 customers within China. The Company sells more than 1,100 products and is actively building a pipeline of proprietary traditional and Chinese herbal remedy products targeting oncology, high blood pressure and the removal of Aflatoxins from food and animal feed. For more information visit the Company's website at http://www.chinamedicinecorp.com .
Safe Harbor Statement
This press release contains forward-looking statements concerning China Medicine Corporation's business and products. The actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, development, shipment, market acceptance, additional competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risks factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release
For more information, please contact:
Lin Li, China Medicine Corporation
|SOURCE China Medicine Corporation|
Copyright©2007 PR Newswire.
All rights reserved